Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomi
about
Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarctionAspect of thrombolytic therapy: a reviewCatheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatmentEnoxaparin in acute coronary syndromesEfficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS dataLow-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.Heparin in interventional radiology: a therapy in evolutionSafety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registryClinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.Tailoring therapy to best suit ST-segment elevation myocardial infarction: searching for the right fit.Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trialOptimizing adjunctive antithrombotic therapy in the treatment of acute myocardial infarction: a role for low-molecular-weight heparin.Myocardial infarction in the elderlyEvolving role of low-molecular-weight heparins in ST-elevation myocardial infarction.Primary Angioplasty for the Treatment of Acute ST-Segment Elevated Myocardial Infarction: An Evidence-Based Analysis.Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction.Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: results of the FARMI trial.Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction.Overview of contemporary reperfusion strategies in acute ST-elevation myocardial infarction.Early reperfusion strategies after acute ST-segment elevation myocardial infarction: the importance of timing.It's a matter of time: contemporary pre-hospital management of acute ST elevation myocardial infarctionA Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients.Delivery of primary percutaneous coronary intervention for the management of acute ST segment elevation myocardial infarction: summary of the Cardiac Care Network of Ontario Consensus Report.ST segment elevation differs depending on the method of measurement.Ambulance diagnosis of ST elevation myocardial infarction eligible for primary PCI.Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.The open-artery hypothesis revisited.Early management of ST elevation myocardial infarction: a review of practice.Fibrinolytic agents for the management of ST-segment elevation myocardial infarction.Utilizing enoxaparin in the management of STEMI.Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction.New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implicationsContinuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibition.Efficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction.Sex differences in mortality following acute coronary syndromes.Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.Safety evaluation of enoxaparin in currently approved indications.Age related issues in reperfusion of myocardial infarction.Enoxaparin: a pharmacologic and clinical review.
P2860
Q22252960-D3F4F0BE-28CA-45CD-8718-5C20E33FBF42Q26999262-0F4CD1CC-E27B-40B4-A379-37EA3334DC5BQ28217792-1C40F071-339F-4910-8D15-14CCC2309D94Q28301431-BFE7581A-A268-432C-85AE-BDE7E9D544FAQ31039791-3AFCE61B-996A-4F83-AC45-42698FBAC9F8Q31039802-8C6E4D0F-BD8E-4178-8308-E9DE51CD2C5AQ31150630-0A9BBD93-8B6F-4644-A690-EB39298F7EADQ33394179-D8E228F1-483D-4293-ACFE-D19A9E4BAABEQ34196711-F032909D-D7EC-4353-B237-6C10D8954A7AQ34255603-A7853CAF-ED15-40C0-87B2-6926AA9C0053Q35569205-B5C030DA-C91D-4B83-B12D-1E5A0AC3E954Q35584911-D23D5BB1-5460-41C0-B58A-3C8636C35EFBQ35638777-8B4C288D-382D-4F95-A6FA-2E37A984BA98Q35806730-67B08A21-F0A2-4E5B-8283-16CB9E08BA7DQ36035257-B6E7B888-B2AC-4AA8-B108-42011836A5F3Q36070782-8E75EFCB-5D2E-4689-AB8A-669C1C8027E3Q36110453-BF909997-0CFC-4E05-B380-1C93D3F745CEQ36172924-AF59D5F0-D238-47E4-9467-E58FC9CEA876Q36213440-556C7C5C-68EB-414D-A4AE-85C4BD2D6FF4Q36216834-64AE9700-24F6-4882-9B31-9E4FCD05A886Q36304213-DB7EBCBB-BAA4-4528-893A-E763B22E295EQ36312981-AE006161-D184-458B-91EE-F0F8819AA0ABQ36363183-4BEA618A-3DA1-4CD0-95CA-E091AA14130BQ36415358-E3BACD7B-ABB4-4252-9D2B-C1D4EFFFDA8CQ36419098-68DAFF32-401E-4823-96CE-F06D9ECE5EE8Q36465696-D7586D49-2CCC-4BE7-B406-33165057C6AEQ36545687-E7C15D1C-C573-48F4-870D-B5C41A3A1085Q36623701-0BAEAD68-1BE3-41F9-9851-B7F34ED777E1Q36739783-7192DF8B-4A82-445B-A3C3-5B83FD795DEBQ36982691-700955C4-9104-4DA8-B295-BE0F611B4A73Q37031371-13776915-506E-4D4A-896C-8854B34829CEQ37167513-FA3427C5-4F55-4893-A13E-02097A5A3BC4Q37193906-BEDCC87C-2F6F-4044-B233-9990D855B4D8Q37226395-EEE5043C-1D87-419B-8E3F-66F51E45F5D4Q37414802-827C2571-C265-46C1-9781-FD815AA778D2Q37424804-76503280-E5D8-4A98-8959-C3E4418BED19Q37490581-2536DB4F-E405-4603-B5A9-48983E31CA17Q37622250-57242DD7-D6DA-41DE-8A46-B732A3028C3CQ37857757-AEDA1A33-EC37-4A78-9143-DDEA19E3127AQ37862264-D417BC5E-EE8C-4031-BF78-81971D267D4F
P2860
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomi
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Efficacy and safety of tenecte ...... egimen (ASSENT)-3 PLUS randomi
@en
Efficacy and safety of tenecte ...... of a New Thrombolytic Regimen
@nl
type
label
Efficacy and safety of tenecte ...... egimen (ASSENT)-3 PLUS randomi
@en
Efficacy and safety of tenecte ...... of a New Thrombolytic Regimen
@nl
prefLabel
Efficacy and safety of tenecte ...... egimen (ASSENT)-3 PLUS randomi
@en
Efficacy and safety of tenecte ...... of a New Thrombolytic Regimen
@nl
P2093
P50
P1433
P1476
Efficacy and safety of tenecte ...... egimen (ASSENT)-3 PLUS randomi
@en
P2093
A A J Adgey
C B Granger
F Van de Werf
F Verheugt
M Mäkijärvi
P Goldstein
P304
P356
10.1161/01.CIR.0000081659.72985.A8
P407
P577
2003-07-07T00:00:00Z